About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
Videos
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Investor
Investor Presentations
A Three Minute Summary
Analysts
Public Filings
AGM Materials
MENU ≡
About
Corporate Overview
Founders
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Contact
Videos
CEO Updates
News
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
CLI Phase II Trial Summary
Platform
Critical Limb Ischemia
News & Media
News / Press Releases
Investor
Investor Presentations
A Three Minute Summary
Analysts
Public Filings
AGM Materials
Contact
Thomas A. Smeenk, BA
President & CEO, Co-Founder
Hemostemix Inc. TSXV:HEM
905-580-4170
tsmeenk@hemostemix.com
